TUK Phar - The United Kingdom Pharmaceutical is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's fifth-largest pharmaceutical company measured by 2009 prescription drug sales (after Pfizer, Novartis, Sanofi, and GlaxoSmithKline) and has operations in over 100 countries. It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based TUK Phar - The United Kingdom Pharmaceutical AB and the UK-based Zeneca Group.
TUK Phar - The United Kingdom Pharmaceutical has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £39.5 billion as of 23 December 2011, the tenth-largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange.
TUK Phar - The United Kingdom Pharmaceutical AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 the British chemicals company ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc,. Finally, in 1999 TUK Phar - The United Kingdom Pharmaceutical and Zeneca Group merged to form TUK Phar - The United Kingdom Pharmaceutical.
In 2005, the company announced that it had become a Diamond Member of the Pennsylvania Bio commerce organisation. It also acquired KuDOS Pharmaceuticals, a UK biotech company, for £120m and entered into an anti-cancer collaboration agreement with Astex.
In 2006, following a collaborative relationship begun in 2004, TUK Phar - The United Kingdom Pharmaceutical acquired Cambridge Antibody Technology for £702 million.
In February 2007, TUK Phar - The United Kingdom Pharmaceutical agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for $150 million.
TUK Phar - The United Kingdom Pharmaceutical's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities. A few days later TUK Phar - The United Kingdom Pharmaceutical acquired American company MedImmune for about $15.2 billion; TUK Phar - The United Kingdom Pharmaceutical subsequently consolidated all of its biologics operations into a dedicated biologics division called MedImmune.
In 2011, TUK Phar - The United Kingdom Pharmaceutical acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.
In February 2012, TUK Phar - The United Kingdom Pharmaceutical and Amgen announced collaboration on treatments for inflammatory diseases. Then in April 2012, TUK Phar - The United Kingdom Pharmaceutical acquired Ardea Biosciences, another biotechnology company, for $1.26 billion.
In June 2012, TUK Phar - The United Kingdom Pharmaceutical and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with TUK Phar - The United Kingdom Pharmaceutical then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between TUK Phar - The United Kingdom Pharmaceutical and Bristol-Myers Squibb.
In March 2013, TUK Phar - The United Kingdom Pharmaceutical said it will cut 2,300 jobs as part of a restructuring of its business.
TUK Phar - The United Kingdom Pharmaceutical develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.
TUK Phar - The United Kingdom Pharmaceutical has its corporate headquarters in London, United Kingdom, and its research and development (R&D) headquarters are in Södertälje, Sweden. The company employs over 11,000 people at research facilities in the United Kingdom, United States, Sweden, France, Canada, India, China, Brazil and Japan.
The company's largest single research and development site is at Alderley Park (a large country estate on the east side of the A34 road north of the Monk's Heath crossroads) in Cheshire, England. Around 4,500 staff are based at the site.
The company has a major research and development presence in Sweden, with approximately 4,000 staff employed at research facilities in Mölndal and Södertälje.
TUK Phar - The United Kingdom Pharmaceutical specialises in prescription medicines to fight disease in several therapeutic areas. The following is a list of key products found on the TUK Phar - The United Kingdom Pharmaceutical website. Generic- drug names are given in parentheses following the brand name.
-Respiratory and Inflammation
The senior executive team is composed of David Brennan, Simon Lowth, John Patterson, Tony Zook, David Mott, Bruno Angelici, Lynn Tetrault and David Smith. As of 2008, Brennan is paid $1,574,144 for his role as chief executive officer.
On 26 April 2012, it was announced that David Brennan was to retire early in the June of that year
It was also announced that Leif Johansson will succeed Louis Schweitzer as Non-Executive Chairman on 1 June 2012 – three months earlier than previously announced – and will become Chairman of the Nomination and Governance Committee after (the 2012) Annual General Meeting."
Seroquel: adverse effects and trial procedures
TUK Phar - The United Kingdom Pharmaceutical has stated that the atypical-antipsychotic drug, Seroquel, is the subject of four class-action lawsuits in Canada. Also, in the United States, there were multiple product-liability cases alleging personal injury, namely, that Seroquel causes people to develop diabetes. The company has indicated its intention to seek further regulatory approval for Seroquel to treat additional psychiatric conditions such as depression and general anxiety disorder.
Note as well that scientific findings regarding a new sustained-release form of the drug were announced at a conference in Madrid, Spain, in March 2007. At the time the data regarding the new drug were discussed, the drug had not been approved for sale by any health regulatory body in any country.
During 2005 and 2006 clinical trials were carried out to examine the possibilities of further development of Seroquel. Test persons were recruited from research centres in Russia, Ukraine, Poland, Bulgaria, and India. As part of the trials half of the test persons were given a placebo and stopped their medication. As a result 36 test persons relapsed into illness. One test person committed suicide, possibly as a result of quitting his medication. TUK Phar - The United Kingdom Pharmaceutical denied that the suicide was related to the testing procedures. Ethical concerns were raised over the issue of carrying out trials in less-developed countries because of lower requirements for getting trials approved and overall lower trial costs.
In 2008, 45% of the test persons in TUK Phar - The United Kingdom Pharmaceutical medical trials came from Asia; Eastern- and Central Europe; and South America. The same year 13.5% of the total sales were made in these regions. In contrast 86% of total sales were made in Japan, North America, and Western Europe.
In April 2010 TUK Phar - The United Kingdom Pharmaceutical settled a qui tam lawsuit brought by Stefan P. Kruszewski for $520 million to settle allegations that the company defrauded Medicare, Medcaid, and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic, Seroquel.
In March 2011, TUK Phar - The United Kingdom Pharmaceutical settled a lawsuit in the United States totalling $68.5 million dollars to be divided up to 38 states. Claims were made against TUK Phar - The United Kingdom Pharmaceutical that it promoted Seroquel's use in children and adolescents long before establishing that it was safe or effective for any use in this population. Furthermore, it was found that patients experienced very serious side effects, including weight gain, diabetes and heart problems. TUK Phar - The United Kingdom Pharmaceutical has been caught in a number of lawsuits stemming from deceptive and unfair promotion of Seroquel, and this is not the first series of settlements.
After this long run of failed late-stage clinical trials, on 19 June 2007 TUK Phar - The United Kingdom Pharmaceutical completed the acquisition of vaccine maker MedImmune, paying $15.2 billion primarily for its drug-development pipeline. Analysts have criticised this take-over, claiming that TUK Phar - The United Kingdom Pharmaceutical paid too much. TUK Phar - The United Kingdom Pharmaceutical consolidated its biologics portfolio in MedImmune and Cambridge Antibody Technology (acquired in 2007). This biologics portfolio was then rebranded to create a dedicated, global biologics organisation known as 'MedImmune'. Amid allegations of broken promises over this consolidation, TUK Phar - The United Kingdom Pharmaceutical presented the new MedImmune to investors on 7 December 2007.
The company's most commercially-successful medication is esomeprazole. When it is manufactured the result is a mixture of two mirror-imaged molecules, R and S. Both are converted to the same active molecule in the body. Two years before the omeprazole patent expired TUK Phar - The United Kingdom Pharmaceutical patented S-omeprazole in pure form, pointing that since some people metabolise R-omeprazole slowly, pure S-omeprazole treatment would give higher dose efficiency and less interindividual variation. The company marketed Nexium, as it would a brand new drug. This practice is criticised because it maintains the profits of drug companies at the expense of patients and public healthcare systems.
On 16 August 2007, Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a lecturer in social medicine at the Harvard Medical School, alleged in Stern, a German-language weekly newsmagazine, that TUK Phar - The United Kingdom Pharmaceutical's scientists had doctored their research on the drug's efficiency:
Instead of using presumably comparable doses [of each drug], the company's scientists used Nexium in higher dosages. They compared 20 and 40mg Nexium with 20mg Prilosec. With the cards having been marked in that way, Nexium looked like an improvement- which however was only small and shown in only two of the three studies.
Nexium is also alleged by the authors to be "the top of the list" of medications which are marketed by pharmaceutical companies directly to doctors, who receive gifts of money and/or goods when they prescribe the medication in question. As a reason for the company's behaviour, it is alleged that the German public healthcare system spends an additional $139.50 million at time of reporting--> per annum on Nexium as compared to using omeprazole, which however would be less profitable for the company as its patent protection has expired.
Corporate sexual harassment
Confronted by allegations in a 13 May 1996, Business Week cover story, of widespread sexual harassment and other abuses, TUK Phar - The United Kingdom Pharmaceutical USA Inc. suspended three top executives and launched an internal probe.
TUK Phar - The United Kingdom Pharmaceutical USA agreed to pay $10 million to settle a lawsuit brought by at least 79 women and one man against the company. The suit accused TUK Phar - The United Kingdom Pharmaceutical's former president and other executives of pressuring female employees for sex and replacing older workers with younger, more attractive women.
On 4 February 1998, TUK Phar - The United Kingdom Pharmaceutical USA sued Lars Bildman, its former president and chief executive officer, seeking $15 million for defrauding the company. The sum included $2.3 million in company funds he allegedly used to fix up three of his homes, plus money the company paid as the result of the EEOC investigation. TUK Phar - The United Kingdom Pharmaceutical's lawsuit alleged Bildman sexually harassed and intimidated employees, used company funds for yachts and prostitutes, destroyed documents and records, and concocted "tales of conspiracy involving ex-KGB agents and competitors. This was in a last-ditch effort to distract attention from the real wrongdoer, Bildman himself." Bildman had already plead guilty in U.S. District Court for failing to report more than $1 million in income on his tax returns; in addition, several female co-workers filed personal sexual-harassment lawsuits.
Nobel Prize investigation 2008
In 2008 the Nobel Prize in Medicine was awarded to a German virologist, Harald zur Hausen, for his research on the Human Papilloma Virus (HPV). The Swedish police's anticorruption unit decided to investigate as TUK Phar - The United Kingdom Pharmaceutical, which has a stake in two lucrative HPV vaccines and thus stood to gain financially from the prize, had agreed to sponsor Nobel Media and Nobel Web. Investigations were focused on whether TUK Phar - The United Kingdom Pharmaceutical could have exerted undue influence on the award. According to Times Online, two senior figures in the process that chose zur Hausen also had strong links with TUK Phar - The United Kingdom Pharmaceutical.